James B. Tananbaum

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
West Hollywood, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ James B. Tananbaum
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for James B. Tananbaum

Form 4 holding Director, 10%+ Owner

Gemini Therapeutics, Inc. /DE

Security class
Common Stock
Shares / value
411,500
Estimated value
$27,837,975
Report date
04 Oct 2021
Price
$67.65
Ownership
Indirect
Form 4 holding Director

Quantum-Si Inc

Security class
Class A Common Stock
Shares / value
4,463,619
Estimated value
$7,900,606
Report date
10 Jun 2021
Price
$1.77
Ownership
Foresite Capital Fund IV, L.P.
Form 4 holding Director, 10%+ Owner

ALUMIS INC.

Security class
Common Stock
Shares / value
680,486
Estimated value
$6,641,543
Report date
01 Apr 2026
Price
$9.76
Ownership
Indirect
Form 4 holding Director

Quantum-Si Inc

Security class
Class A Common Stock
Shares / value
2,342,061
Estimated value
$4,145,448
Report date
10 Jun 2021
Price
$1.77
Ownership
Foresite Capital Fund V, L.P.
Form 4 holding Director

Quantum-Si Inc

Security class
Class A Common Stock
Shares / value
1,598,125
Estimated value
$2,828,681
Report date
10 Jun 2021
Price
$1.77
Ownership
By Foresite Capital Opportunity Fund V, L.P.
Form 4 holding Director

Quantum-Si Inc

Security class
Class A Common Stock
Shares / value
20,512
Estimated value
$36,306
Report date
11 Jun 2021
Price
$1.77
Ownership
Direct
Form 4 holding President and CEO, Director, 10%+ Owner

PARDES BIOSCIENCES, INC.

Security class
Common Stock
Shares / value
1,000
Estimated value
$1,500
Report date
31 Aug 2023
Price
$1.50
Ownership
Indirect
Form 4 holding Director, 10%+ Owner

Kinnate Biopharma Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
03 Apr 2024
Price
$2.59
Ownership
By Fund
Form 4 holding Director, 10%+ Owner

Gemini Therapeutics, Inc. /DE

Security class
Stock Option (Right to Buy)
Shares / value
17,245
Estimated value
Report date
04 Oct 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Kinnate Biopharma Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
03 Apr 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President and CEO, Director, 10%+ Owner

PARDES BIOSCIENCES, INC.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
31 Aug 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by James B. Tananbaum

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .